Carolin Zimpel

Luebeck, SH, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Early C-reactive protein kinetics predict outcomes in unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors: a multicenter, observational study comparing different C-reactive protein kinetic definitions.

Early C-reactive protein kinetics predict outcomes in unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors: a multicenter, observational study comparing different C-reactive protein kinetic definitions.

Journal: Frontiers in oncology

Published: June 02, 2026

Circulating extracellular vesicles carrying PD-1, PD-L1 and CTLA-4 inform resistance to anti-PD-L1-based therapy in HCC.

Circulating extracellular vesicles carrying PD-1, PD-L1 and CTLA-4 inform resistance to anti-PD-L1-based therapy in HCC.

Journal: Gut

Published: November 21, 2025

Hepatocellular Carcinoma: from Screening to Therapy

Hepatocellular Carcinoma: from Screening to Therapy

Journal: Deutsche medizinische Wochenschrift (1946)

Published: October 10, 2025

Clinical practice and implications of biomarker testing in biliary tract cancer: An observational study.

Clinical practice and implications of biomarker testing in biliary tract cancer: An observational study.

Journal: JHEP reports : innovation in hepatology

Published: May 29, 2025

Metabolomic liquid biopsy dynamics predict early-stage HCC and actionable candidates of human hepatocarcinogenesis.

Metabolomic liquid biopsy dynamics predict early-stage HCC and actionable candidates of human hepatocarcinogenesis.

Journal: JHEP reports : innovation in hepatology

Published: October 14, 2024

Efficacy, safety and differential outcomes of immune-chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: A multicenter real world cohort.

Efficacy, safety and differential outcomes of immune-chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: A multicenter real world cohort.

Journal: United European gastroenterology journal

Published: May 15, 2024

PARP-1 selectively impairs KRAS-driven phenotypic and molecular features in intrahepatic cholangiocarcinoma.

PARP-1 selectively impairs KRAS-driven phenotypic and molecular features in intrahepatic cholangiocarcinoma.

Journal: Gut

Published: October 19, 2023

Prospective study of computer-aided detection of colorectal adenomas in hospitalized patients.

Prospective study of computer-aided detection of colorectal adenomas in hospitalized patients.

Journal: Scandinavian journal of gastroenterology

Published: May 16, 2023

Current Studies and Evidence in Cholangiocarcinoma

Current Studies and Evidence in Cholangiocarcinoma

Journal: Zentralblatt fur Chirurgie

Published: July 21, 2022

Markers of cell death predict therapy response in patients with cirrhosis and hepatorenal syndrome.

Markers of cell death predict therapy response in patients with cirrhosis and hepatorenal syndrome.

Journal: United European gastroenterology journal

Published: July 17, 2022

13 C-Methacetin Breath Test Predicts Survival in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.

13 C-Methacetin Breath Test Predicts Survival in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.

Journal: Clinical and translational gastroenterology

Published: June 08, 2022

Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers.

Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers.

Journal: Cancers

Published: February 07, 2022

Showing 1-12 of 13

Last Updated: 09/26/2026